Table 1.
Demographic, psychopathological, neuropsychological characteristics and serum IGF-1 levels in HC and MDD patients
| HC n = 47 |
MDD n = 78 |
p | |
|---|---|---|---|
| Demographic characteristics | |||
| Women, n (%) | 27 (57.4%) a | 48 (61.5%) | 0.65 |
| Age, years* | 37.8 (12.3) b | 38.2 (11.9) | 0.84 |
| Education, years* | 15.2 (2.1) b | 14.5 (1.9) | 0.60 |
| Clinical assessments | |||
| Psychopathological | |||
| MADRS total score | 2 (0–4) c | 29 (22–33) | < 0.0001 |
| CGI-S score | 1 (1–1) c | 4 (4–5) | < 0.0001 |
| Patient-reported cognitive symptoms | |||
| PDQ-5 total score | 1 (0–2) c | 7 (5–11) | < 0.0001 |
| Neuropsychological testing | |||
| RAVLT immediate recall total score | 64 (58–69) c | 49 (43–56) | < 0.0001 |
| RAVLT proactive interference score | 8 (6–9) c | 6 (5–7) | < 0.0001 |
| RAVLT retroactive interference score | 15 (13–15) c | 11 (9–12) | < 0.0001 |
| RAVLT delayed recall score | 15 (14–15) c | 11 (9–12) | < 0.0001 |
| RAVLT delayed recognition score | 15 (15–15) c | 14 (14–15) | < 0.0001 |
| TMT-B (s) | 57 (42–65) c | 77 (64–93) | < 0.0001 |
| DSST number of correct symbols | 62 (54–68) c | 50 (43–59) | < 0.0001 |
| IGF-1 serum level (ng/ml) | 153 (129–186) c | 228 (183–312) | < 0.0001 |